Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023586 | 0.86 | KAT2B (0.43) | KAT2BBAZ2BL3MBTL1BACE1 | |
| Hydrochloric Acid SCHEMBL3966985 | 0.84 | KAT2B (0.42) | KAT2BBAZ2BL3MBTL1BACE1 | |
| SCHEMBL697518 | 0.84 | — | — | |
| SCHEMBL698654 | 0.79 | — | — | |
| SCHEMBL305952 | 0.79 | EPHX1 (0.43) | — | |
| SCHEMBL73973 | 0.78 | KAT2B (0.42) | KAT2BBAZ2BL3MBTL1 | |
| SCHEMBL1497921 | 0.78 | L3MBTL1 (0.35) | KAT2BBAZ2BL3MBTL1 | |
| SCHEMBL10598876 | 0.77 | EPHX1 (0.47) | — | |
| SCHEMBL8582703 | 0.77 | EPHX1 (0.47) | — | |
| SCHEMBL72976 | 0.77 | EPHX1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | claimed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | claimed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | claimed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-9464071-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-10-11 | — | — | US | disclosed |
| US-9458158-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2016-10-04 | — | — | US | disclosed |
| US-9447098-B2 | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9439896-B2 | Quinolines as FGFR kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2016-09-13 | — | — | US | disclosed |
| US-20060178361-A1 | ATM inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
| US-20060172019-A1 | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders | ABERDEEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF (GB) | 2006-08-03 | — | — | US | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-7049313-B2 | ATM inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-05-23 | — | — | US | disclosed |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20040002492-A1 | Induce immunology response; anticancer agents | KUDOS PHARMACEUTICALS LTD (GB) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002492-A1 | Induce immunology response; anticancer agents | MYD88, IFNG, HCCS | KAT2B 2397/4885BAZ2B 405/4885L3MBTL1 2434/4885 |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | KAT2B 1160/4885BAZ2B 782/4885L3MBTL1 1346/4885 |
| US-20060172019-A1 | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders | CNR2, CNR1, GPER1 | KAT2B 2617/4885BAZ2B 557/4885L3MBTL1 3234/4885 |
| US-20060178361-A1 | ATM inhibitors | ATM, CHEK2, ATR | KAT2B 499/4885BAZ2B 1939/4885L3MBTL1 2018/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | KAT2B 169/4885BAZ2B 582/4885L3MBTL1 4143/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | KAT2B 2884/4885BAZ2B 101/4885L3MBTL1 1129/4885 |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | KAT2B 1443/4885BAZ2B 1360/4885L3MBTL1 2743/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | KAT2B 1881/4885BAZ2B 1619/4885L3MBTL1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.